Selected publications
Royston et al, Neuro-Oncology Advances, 6(1), vdae144 (2024)
Funato et al, Cell Stem Cell 28, 894-905.e7 (2021)
Funato et al, EMBO Rep. 19:e45587 (2018)
Funato et al, Science 346, 1529-1533 (2014)
Publications
2020-2024
Royston HN, Hampton AB, Bhagat D, Pinto EF, Emerson MD, Funato K, A human embryonic stem cell-based model reveals the cell of origin of FOXR2-activated CNS neuroblastoma, Neuro-Oncology Advances, 2024; 6(1), vdae144 [Link]
Saito Y, Yang Y, Saito M, Park CY, Funato K, Tabar V, Darnell RB. NOVA1 acts as an oncogenic RNA-binding protein to regulate cholesterol homeostasis in human glioblastoma cells Proceedings of the National Academy of Sciences 2024; 121 (10), e2314695121, PMID:38416679 [Link]
Funato K, Smith RS, Saito Y, Tabar V. Dissecting the impact of regional identity and the oncogenic role of human-specific NOTCH2NL in an hESC model of H3.3G34R-mutant glioma. Cell Stem Cell 2021; 28, 894-905.e7, PMID: 33631117 [Link]
Wang R, Sharma R, Shen X, Laughney AM, Funato K, Clark PJ, Shpokayte M, Morgenstern P, Navare M, Xu Y, Harbi S, Masilionis I, Nanjangud G, Yang Y, Duran-Rehbein G, Hemberg M, Pe'er D, Tabar V. Adult Human Glioblastomas Harbor Radial Glia-like Cells. Stem Cell Reports. 2020; 15(1):275-277, PMID: 32668221 [Link] [PDF]
2015-2019
Phillips RE, Yang Y, Smith RC, Thompson BM, Yamasaki T, Soto-Feliciano YM, Funato K, Liang Y, Garcia-Bermudez J, Wang X, Garcia BA, Yamasaki K, McDonald JG, Birsoy K, Tabar V, Allis CD. Target identification reveals lanosterol synthase as a vulnerability in glioma. Proc Natl Acad Sci U S A. 2019; 116(16):7957-7962, PMID: 30923116, PMCID: PMC6475387 [Link] [PDF]
Funato K*, Hayashi T*, Echizen K, Negishi L, Shimizu N, Koyama-Nasu R, Nasu-Nishimura Y, Morishita Y, Tabar V, Todo T, Ino Y, Mukasa A, Saito N, Akiyama T. SIRT2‐mediated inactivation of p73 is required for glioblastoma tumorigenicity. EMBO Reports 2018; e45587 (*These authors contributed equally to this work), PMID: 30213795, PMCID: PMC6216266 [Link] [PDF]
Funato K and Tabar V, Histone Mutations in Cancer, Annual Review of Cancer Biology 2018; 2:337-51
Yamazumi Y, Sasaki O, Imamura M, Oda T, Ohno Y, Shiozaki-Sato Y, Nagai S, Suyama S, Kamoshida Y, Funato K, Yasui T, Kikutani H, Yamamoto K, Dohi M, Koyasu S, Akiyama T. The RNA Binding Protein Mex-3B Is Required for IL-33 Induction in the Development of Allergic Airway Inflammation. Cell reports 2016; 16(9):2456-71, PMID: 27545879 [Link]
Hicks MJ, Chiuchiolo MJ, Ballon D, Dyke JP, Aronowitz E, Funato K, Tabar V, Havlicek D, Fan F, Sondhi D, Kaminsky SM, Crystal RG. Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PloS one 2016; 11(10):e0162978, PMID: 27711187, PMCID: PMC5053413 [Link] [PDF]
2010-2014
Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science 2014; 346(6216):1529-1533, (Perspectives in Science 346: 1458-1459), PMID: 25525250, PMCID: PMC4995593 [Link] [PDF]
Hicks MJ*, Funato K*, Wang L, Aronowitz E, Dyke JP, Ballon DJ, Havlicek DF, Frenk EZ, De BP, Chiuchiolo MJ, Sondhi D, Hackett NR, Kaminsky SM, Tabar V, Crystal RG. Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Therapy 2015; 22(1):1–8 (*These authors contributed equally to this work), PMID: 25501993, PMCID: PMC4293257 [Link] [PDF]
Koyama-Nasu R, Nasu-Nishimura Y, Todo T, Ino Y, Saito N, Aburatani H, Funato K, Echizen K, Sugano H, Haruta R, Matsui M, Takahashi R, Manabe E, Oda T, Akiyama T. The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. Oncogene 2013; 32(33):3840-5, PMID: 22964630 [Link]
Koyama-Nasu R, Haruta R, Nasu-Nishimura Y, Taniue K, Katou Y, Shirahige K, Todo T, Ino Y, Mukasa A, Saito N, Matsui M, Takahashi R, Hoshino-Okubo A, Sugano H, Manabe E, Funato K, Akiyama T. The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells. Oncogene 2014; 33(17):2236-44, PMID: 23686309 [Link]
Funato K, Yamazumi Y, Oda T, Akiyama T. Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Exp Ther Med. 2011; 2(3):457-463, PMID: 22977525, PMCID: PMC3440690 [Link]